Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF FINANCIAL OFFICER

CHIEF COMMERCIAL OFFICER

SVP, CHIEF ACCOUNTING OFFICER

SENIOR VICE PRESIDENT, R&D

SVP, GC & CORPORATE SECRETARY

CHIEF MEDICAL OFFICER

CHIEF EXECUTIVE OFFICER

Chief Medical Officer

Chief Commercial Officer

Chief Executive Officer

SVP, GC & Corporate Secretary

Chief Financial Officer

Senior Vice President, R&D

SVP, Chief Accounting Officer

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of ...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-05-08	Premium	acquired	Premium	Premium	Premium	-
2024-04-11	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-01	Premium	sold	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-02-01	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-01	Premium	sold	Premium	Premium	Premium	SVP, CHIEF ACCOUNTING OFFICER
2024-02-01	Premium	sold	Premium	Premium	Premium	SENIOR VICE PRESIDENT, R&D
2024-02-01	Premium	sold	Premium	Premium	Premium	SVP, GC & CORPORATE SECRETARY
2024-02-01	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-01	Premium	sold	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-01-31	Premium	acquired	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-01-31	Premium	acquired	Premium	Premium	Premium	SVP, CHIEF ACCOUNTING OFFICER
2024-01-31	Premium	acquired	Premium	Premium	Premium	SENIOR VICE PRESIDENT, R&D
2024-01-31	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-01-31	Premium	acquired	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-01-31	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-01-31	Premium	acquired	Premium	Premium	Premium	SVP, GC & CORPORATE SECRETARY
2024-01-23	Premium	sold	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER

TVTX - Travere Therapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for TVTX